PM360

APRIL 7, 2023

Most immediately, it will add confusion in the healthcare space,” explains Daniel Sontupe, Associate Partner, Managing Director, The Bloc Value Builders. This will create confusion in the marketplace and may possibly lead to delivery of misinformation to healthcare providers (HCPs) regarding a brand’s drug coverage,” Bambalas says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. ablation market and would have a total global market value of $3 billion.

Marketing 52

Marketing Competition FDA Electronics 52

pharmaphorum

SEPTEMBER 13, 2022

Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. However, myelodysplastic syndromes and myeloproliferative neoplasms are also prominent types of blood cancer.

Food and Drug Administration 87

Food and Drug Administration Patients Engineering Physicians 87

pharmaphorum

OCTOBER 10, 2022

Any delay in diagnosis or treatment can severely impact the options available to patients and healthcare professionals. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028. Forewarned is forearmed. August 2022. About the panel.

Patients 90

Patients Pharma Media Training 90

World of DTC Marketing

DECEMBER 15, 2021

People are living longer, but there is a prediction of a global lack of healthcare workers to look after them, with a shortfall of 9.9 Physicians have not bought into the hype around apps. At best, health apps can alert users to potential problems, but only a trained health care professional can diagnose problems. The Economist.

Doctors 208

Doctors Medical Patients Marketing 208

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics).

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

World of DTC Marketing

JULY 28, 2022

Late last year, the Senate Finance Committee released draft legislation enabling Medicare negotiation for up to 10 drugs in 2025, 15 in 2026 and 2027, and 20 in 2028 and beyond. This would include drugs covered by both Medicare Part B (physician-administered drugs) and Part D (prescription medications). The secretary of the U.S.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256